An Interview with Michael D. Iseman, M.D.

Professor of Medicine, University of Colorado School of Medicine, Denver, Colorado

This video was recorded on November 13, 2009 at Johns Hopkins University.

MIchael D. Iseman
Michael D. Iseman

Dr. Michael D. Iseman is a Professor of Medicine in the Divisions of Pulmonary Medicine and Infectious Diseases at the University of Colorado School of Medicine.

Dr. Iseman grew up in Fremont, Nebraska. He received an A.B. with honors in history from Princeton University in 1961 and an M.D. from Columbia College of Physicians and Surgeons in 1965.

After his internship and junior residency in medicine at the Columbia service at Bellevue Hospital (1965-1967), he served as a medical officer in the U.S. Navy (1967-1969). He returned to New York City to complete his medicine residency and fellowship in pulmonary medicine on the Columbia Service at Harlem Hospital (1969-1972).

In 1972 he joined the faculty of the University of Colorado School of Medicine. For 10 years he was on the staff of Denver General Hospital, including directorship of the Metropolitan TB Clinic.

In 1982, Dr. Iseman joined the faculty of the National Jewish Medical and Research Center, acting as Director of the Mycobacterial Disease Service from 1982-2004. He served as an Associate Editor (for TB) for the American Journal of Respiratory and Critical Care Medicine from 1984 to 1989 and was Editor-in-Chief of The International Journal of Tuberculosis and Lung Disease (Paris) from 1997-2002.

In addition to numerous articles and editorials, Dr. Iseman single-authored a textbook, “A Clinician’s Guide to Tuberculosis” (Lippincott, 2000). He has lectured in 47 states and 36 foreign countries and has served as a consultant to the U.S. Centers for Disease Control and the World Health Organization for TB. Dr. Iseman has been Director of “The Denver TB Course” from 1983 to the present, hosting over 3,000 physicians, nurses and public health workers in this period.

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...